Early Control of PTH and FGF23 in Normophosphatemic CKD Patients
Open Access
- 1 February 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 5 (2), 286-291
- https://doi.org/10.2215/cjn.05420709
Abstract
Background and objectives: Levels of parathyroid hormone (PTH) and the phosphaturic hormone FGF23, a fibroblast growth factor (FGF) family member, increase early in chronic kidney disease (CKD) before the occurrence of hyperphosphatemia. This short-term 6-wk dose titration study evaluated the effect of two phosphate binders on PTH and FGF23 levels in patients with CKD stages 3 to 4. Design, setting, participants, and measurements: Patients were randomized to receive over a 6-wk period either calcium acetate (n = 19) or sevelamer hydrochloride (n = 21). Results: At baseline, patients presented with elevated fractional excretion of phosphate, serum PTH, and FGF23. During treatment with both phosphate binders there was a progressive decline in serum PTH and urinary phosphate, but no change in serum calcium or serum phosphate. Significant changes were observed for FGF23 only in sevelamer-treated patients. Conclusions: This study confirms the positive effects of early prescription of phosphate binders on PTH control. Prospective and long-term studies are necessary to confirm the effects of sevelamer on serum FGF23 and the benefits of this decrease on outcomes.Keywords
This publication has 22 references indexed in Scilit:
- FGF-23 as a Predictor of Renal Outcome in Diabetic NephropathyClinical Journal of the American Society of Nephrology, 2011
- A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney diseaseKidney International, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisThe New England Journal of Medicine, 2008
- Trends in Mineral Metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004American Journal of Kidney Diseases, 2008
- FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal TransplantationNephron Physiology, 2006
- Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and WomenJournal of Bone and Mineral Research, 2006
- Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure ratsKidney International, 2006
- Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolismAmerican Journal of Physiology-Renal Physiology, 2005
- Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis PatientsTherapeutic Apheresis and Dialysis, 2005
- On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dogJCI Insight, 1971